Collaboration combines clinical research expertise with artificial intelligence capabilities to help drug developers better understand the probability of clinical success...
Completed dosing in first cohort of Phase 1/2 GALILEO-1 trial of FLT201 in Gaucher disease; expect to report initial clinical...
Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) Approved for Adults Living with Late-Onset Pompe Disease in Great Britain National Institute for...
Conference Call to be Held Today at 8:30 A.M. ETHOUSTON, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH),...
Gross profit increases 178% compared to the same period last year New online store providing greater interaction with dentists and...
Agreement provides nonexclusive access to Genevant’s leading LNP technology for use with Gritstone bio’s self-amplifying RNA technology in wide array of...
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, ON, Aug. 15, 2023 (GLOBE...
– Continued operational execution across pipeline towards multiple clinical and regulatory value-driving milestones expected in the second half of 2023...
RESEARCH TRIANGLE PARK, N.C., Aug. 15, 2023 (GLOBE NEWSWIRE) -- Merakris Therapeutics has added two new executives to its leadership...
Announced pricing of approximately $5 million equity financing (approximately $5.7 million if underwriter’s overallotment option is exercised in full); expected...
Net Loss and Earnings per Diluted Share of $13.6 million and $1.02 Adjusted EBITDA was a $5.7 million loss, a...
FORT WORTH, Texas, Aug. 15, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (the “Company”), a clinical-stage biopharmaceutical company...
ColoAlert® Revenue Increases 108% Year Over Year in the First Six Months of 2023 ColoFuture and eAArly Detect Studies on...
This document in English is a translation of the original in Swedish. In case of any discrepancy, the Swedish original...
Mylight study met its primary efficacy endpoint and showed no clinically meaningful differences to reference afliberceptResults offer hope of new...
Increase in Cresemba® and Zevtera® related revenue to CHF 80.5 million (+57% year-on-year) Increase in operating profit to CHF 36.9...
Ad hoc announcement pursuant to Art. 53 LR ALLSCHWIL, Switzerland, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX),...
Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules Tecan reports solid underlying sales growth...
Greenville, South Carolina, Aug. 14, 2023 (GLOBE NEWSWIRE) -- ARCpoint Inc. (TSXV: ARC) (the “Company” or “ARCpoint”) a leading US-based...
VANCOUVER, British Columbia, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company"),...